-
公开(公告)号：US20230083417A1
公开(公告)日：2023-03-16
申请号：US17797450
申请日：2021-02-19
IPC分类号： A61K31/5415 , A61K31/437 , A61K31/444 , A61K31/4188 , A61K31/519 , A61K31/513 , A61K31/197 , A61K31/506 , A61K31/5377 , A61K31/416 , A61P9/10
摘要： The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.
-
2.发明申请公开(公告)号：US20200316259A1
公开(公告)日：2020-10-08
申请号：US16753351
申请日：2018-10-05
摘要： The disclosure relates to methods of making an osteoconductive polymer article for use as an orthopedic implant comprises steps of forming an article from a biocompatible, non-biodegradable polymer, the article comprising a non-flat surface with roughness Ra of at least 5 μm; providing a dispersion of bioactive ceramic particles of particle size at most 10 μm in a first solvent comprising a solvent for the polymer; coating at least the non-flat surface with the dispersion in at least one step; and rinsing the coated article with a second solvent being a non-solvent for the polymer to substantially remove the first solvent. Further disclosed is an osteoconductive polymer article for use as an orthopedic implant, which article is made from a biocompatible, non-biodegradable polymer and comprises a non-flat surface with roughness Ra of at least 5 μm, wherein bioactive ceramic particles of particle size at most 10 μm are partly embedded in the polymer at the surface of the article. The methods exhibit benefits in ease of modifying a surface layer with bioactive particles, applying mild conditions and not requiring use of further additives or post-treatments, or without significantly affecting bulk polymer properties, and result in an orthopedic implant article having particles adhering to the surface while still being accessible for interaction with surrounding tissue or fluid.
-
公开(公告)号：US10139407B2
公开(公告)日：2018-11-27
申请号：US15095636
申请日：2016-04-11
IPC分类号： G01N33/48 , G01N33/569 , G01N25/18 , G01N25/20 , G01N33/487 , G01N33/543
摘要： A method for characterizing bacteria includes passing a liquid containing an analyte comprising a first bacteria and a second bacteria over and in contact with a polymer material on a substrate. The polymer material is formulated to bind to the first bacteria, and the first bacteria binds to the polymer material with a higher affinity than the second bacteria. A heat transfer property of the polymer material varies based on an amount of the analyte bound thereto. The method further includes binding a portion of the first bacteria and the second bacteria of the analyte to the polymer material, removing at least a portion of the second bacteria from the polymer material, detecting a temperature of the substrate, and calculating a concentration of the first bacteria in the liquid based at least in part on the temperature of the substrate.
-
公开(公告)号：US09790545B2
公开(公告)日：2017-10-17
申请号：US13864778
申请日：2013-04-17
申请人： UNIVERSITEIT MAASTRICHT , Academisch Ziekenhuis Maastricht , Rijksinstituut Voor Volksgezondheid en Milieu
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6837 , C12Q1/6876 , C12Q2600/142
摘要： This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic.
-
5.发明申请METHOD FOR DETERMINING THE NEURODEVELOPMENTAL TOXICITY OF A COMPOUND IN VITRO 有权用于测定体外化合物的神经发育毒性的方法公开(公告)号：US20130316924A1
公开(公告)日：2013-11-28
申请号：US13864778
申请日：2013-04-17
申请人： UNIVERSITEIT MAASTRICHT , Rijksinstituut Voor Volksgezondheid en Milieu , Academisch Ziekenhuis Maastricht
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6837 , C12Q1/6876 , C12Q2600/142
摘要： This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic.
摘要翻译： 本发明在医学分子诊断领域。 它提供了通过确定有限数量的基因的基因表达来体外检测化合物的神经发育毒性的方法和手段。 更具体地说，本发明涉及确定化合物是神经发育毒性的可能性的方法，其包括以下步骤：提供胚胎干细胞，使干细胞形成胚状体，允许胚状体分化为神经细胞， 所述化合物的存在，从而产生神经分化培养物，从所述神经分化培养物中的细胞中提取总RNA，确定基因Hoxb6，Nrk，1700011H14Rik和Tph1的表达水平，将表达水平与预定参考值进行比较并确定 相对于参考值的表达水平的增加或减少，其中表达值的相对增加或减少大于20％表明化合物是神经发育毒性的。
-
公开(公告)号：US20230095167A1
公开(公告)日：2023-03-30
申请号：US17801469
申请日：2021-02-19
申请人： Universiteit Maastricht , Academisch Ziekenhuis Maastricht , Roche Diagnostics Operations, Inc.
发明人： Alfred Engel , Michael Gerg , Ute Jucknischke , Johann Karl , Peter Kastner , Thomas Meier , Lars Hillringhaus , Ulrich Schotten , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler , Roberto Latini , Jennifer Marie Theresia Anna Meessen
摘要： The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
-
7.发明申请公开(公告)号：US20220323651A1
公开(公告)日：2022-10-13
申请号：US17849893
申请日：2022-06-27
摘要： The disclosure relates to methods of making an osteoconductive polymer article for use as an orthopedic implant comprises steps of forming an article from a biocompatible, non-biodegradable polymer, the article comprising a non-flat surface with roughness Ra of at least 5 μm; providing a dispersion of bioactive ceramic particles of particle size at most 10 μm in a first solvent comprising a solvent for the polymer; coating at least the non-flat surface with the dispersion in at least one step; and rinsing the coated article with a second solvent being a non-solvent for the polymer to substantially remove the first solvent.
-
公开(公告)号：US11078544B2
公开(公告)日：2021-08-03
申请号：US16289897
申请日：2019-03-01
IPC分类号： C12Q1/68 , C12Q1/6886
摘要： This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
-
公开(公告)号：US20190125838A1
公开(公告)日：2019-05-02
申请号：US16092680
申请日：2017-03-31
摘要： The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
-
公开(公告)号：US20190125837A1
公开(公告)日：2019-05-02
申请号：US16092671
申请日：2017-03-31
摘要： The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
-
-
-
-
-
-
-
-
-
搜索结果
55 条记录 (耗时 0.02 秒)